Page 3 - Roger Adsett News Today

Investment analysts at Guggenheim assumed coverage on shares of Insmed (NASDAQ:INSM – Get Free Report) in a report released on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $50.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price would indicate a potential upside of 145.10% from the stock’s current price. Separately, […]

Insmed Incorporated (NASDAQ:INSM – Free Report) – Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Insmed in a research note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings per share of ($4.67) for the year. The consensus estimate […]

Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have earned an average rating of “Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have covered the stock in the last […]

Insmed Incorporated (NASDAQ:INSM – Free Report) has been given an average recommendation of “Buy” by the eleven research firms that are presently covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in […]

StockNews.com upgraded shares of Insmed (NASDAQ:INSM – Free Report) from a sell rating to a hold rating in a research note published on Friday. Insmed Price Performance Shares of NASDAQ:INSM opened at $21.10 on Friday. The stock has a market cap of $2.88 billion, a PE ratio of -4.94 and a beta of 1.53. The […]

Insmed (NASDAQ:INSM – Get Rating) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday. INSM has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price target on shares of Insmed in […]

Shares of Insmed Incorporated (NASDAQ:INSM – Get Rating) have earned an average rating of “Buy” from the eleven analysts that are presently covering the company, Marketbeat reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in […]

Insmed Incorporated (NASDAQ:INSM – Get Rating) COO Roger Adsett sold 8,981 shares of the company’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $19.32, for a total transaction of $173,512.92. Following the completion of the sale, the chief operating officer now owns 151,352 shares of the […]

Neo Ivy Capital Management lowered its stake in shares of Insmed Incorporated (NASDAQ:INSM – Get Rating) by 32.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,790 shares of the biopharmaceutical company’s stock after selling 2,841 shares during the quarter. Neo Ivy Capital Management’s […]

StockNews.com lowered shares of Insmed (NASDAQ:INSM – Get Rating) from a hold rating to a sell rating in a research note published on Thursday morning. A number of other equities research analysts have also recently commented on INSM. Barclays dropped their target price on Insmed from $37.00 to $35.00 and set an overweight rating on […]